Antibe Therapeutics Ownership
| ATBPF Stock | USD 0.22 0.00 0.00% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Antibe |
Antibe Pink Sheet Ownership Analysis
The company has price-to-book (P/B) ratio of 0.61. Some equities with similar Price to Book (P/B) outperform the market in the long run. Antibe Therapeutics recorded a loss per share of 0.41. The entity last dividend was issued on the 1st of December 2020. The firm had 1:10 split on the 1st of December 2020. Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Antibe Therapeutics Inc. was incorporated in 2009 and is headquartered in Toronto, Canada. Antibe Therapeutics is traded on OTC Exchange in the United States.The quote for Antibe Therapeutics is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. For more info on Antibe Therapeutics please contact LLB JD at 416 922 3460 or go to https://www.antibethera.com.Currently Active Assets on Macroaxis
Other Information on Investing in Antibe Pink Sheet
Antibe Therapeutics financial ratios help investors to determine whether Antibe Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Antibe with respect to the benefits of owning Antibe Therapeutics security.